Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 18/20 | 0.91 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.91 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19491654 | 1.00 | STING1 (0.91) | STING1PDE3BPDE3A | |
| SCHEMBL18963754 | 1.00 | STING1 (0.91) | STING1PDE3BPDE3A | |
| SCHEMBL18963689 | 1.00 | STING1 (0.91) | STING1PDE3BPDE3A | |
| SCHEMBL19502704 | 1.00 | STING1 (0.91) | STING1PDE3BPDE3A | |
| SCHEMBL19503140 | 1.00 | STING1 (0.91) | STING1PDE3BPDE3A | |
| SCHEMBL23350871 | 1.00 | STING1 (0.91) | STING1PDE3BPDE3A | |
| SCHEMBL18963752 | 1.00 | STING1 (0.91) | STING1PDE3BPDE3A | |
| SCHEMBL12671632 | 0.96 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL17974376 | 0.96 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL21498373 | 0.96 | STING1 (1.00) | STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2021-05-13 | — | — | US | disclosed |
| US-20170298139-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298139-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | STING1 1/4885PDE3B 488/4885PDE3A 581/4885 |
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | STING1 1/4885PDE3B 488/4885PDE3A 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.